Cellectar Biosciences to Present at Two Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CEO, will present at the following investor conferences in September and be available for 1x1 meetings:

H.C. Wainwright 22nd Annual Global Investment Conference
Date:		Tuesday, September 15, 2020
Time:		3:30 pm Eastern Time
Format:		Virtual Presentation and 1x1 meetings
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date:		Monday, September 21, 2020
Time:		4:10 pm Eastern Time
Format:		Virtual Presentation and 1x1 meetings

A replay of the presentation and webcast will be on the Investor Relations section of the company’s website available for 90 days here. 

About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.